ES2149254T3 - Modulacion especifica del sistema inmunitario. - Google Patents

Modulacion especifica del sistema inmunitario.

Info

Publication number
ES2149254T3
ES2149254T3 ES94901598T ES94901598T ES2149254T3 ES 2149254 T3 ES2149254 T3 ES 2149254T3 ES 94901598 T ES94901598 T ES 94901598T ES 94901598 T ES94901598 T ES 94901598T ES 2149254 T3 ES2149254 T3 ES 2149254T3
Authority
ES
Spain
Prior art keywords
antigen
immune system
specific modulation
presents
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94901598T
Other languages
English (en)
Inventor
Richard L Edelson
Francis P Gasparro
Robert E Tigelaar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES2149254T3 publication Critical patent/ES2149254T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PREVEEN LOS METODOS Y COMPOSICIONES FARMACEUTICAS PARA MODIFICAR LAS RESPUESTA INMUNE DE UN MAMIFERO A UN ANTIGENO ESPECIFICO. LOS METODOS INCLUYEN UN ANTIGENO QUE PRESENTA LA CELULA PARA INCREMENTAR LA EXPRESION DE UNA MOLECULA COMPLEJA DE MAYOR HISTOCOMPATIBILIDAD Y REACCIONAR EL ANTIGENO TRATADO QUE PRESENTA LA CELULA CON EL ANTIGENO EXTRACORPOREAMENTE PARA FORMAR UN ANTIGENO ASOCIADO DE ANTIGENO QUE PRESENTA LA CELULA.
ES94901598T 1992-11-18 1993-11-18 Modulacion especifica del sistema inmunitario. Expired - Lifetime ES2149254T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/977,672 US5651993A (en) 1992-11-18 1992-11-18 Specific immune system modulation
PCT/US1993/011220 WO1994011016A1 (en) 1992-11-18 1993-11-18 Specific immune system modulation

Publications (1)

Publication Number Publication Date
ES2149254T3 true ES2149254T3 (es) 2000-11-01

Family

ID=25525390

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94901598T Expired - Lifetime ES2149254T3 (es) 1992-11-18 1993-11-18 Modulacion especifica del sistema inmunitario.

Country Status (10)

Country Link
US (2) US5651993A (es)
EP (1) EP0668772B1 (es)
JP (1) JPH08503470A (es)
AT (1) ATE195875T1 (es)
DE (1) DE69329344T2 (es)
DK (1) DK0668772T3 (es)
ES (1) ES2149254T3 (es)
GR (1) GR3034908T3 (es)
PT (1) PT668772E (es)
WO (1) WO1994011016A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585512B1 (en) * 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
US5798335A (en) * 1993-09-24 1998-08-25 Peptide Technology Limited Method for the treatment or prevention of eczema/dermatitis
US6168787B1 (en) * 1995-04-24 2001-01-02 John Wayne Cancer Institute Pluripotent vaccine against enveloped viruses
US20020098469A1 (en) * 1996-03-22 2002-07-25 Morgan ,Lewis, Bockius Llp Extracorporeal methods for enhancing antigen presentation and immune responsiveness
CA2249412A1 (en) * 1996-03-22 1997-09-25 Yale University Methods for inducing immune responsiveness in a subject
CN1121217C (zh) * 1996-03-29 2003-09-17 特拉科斯有限公司 免疫原性组合物
US6228995B1 (en) 1996-04-09 2001-05-08 Therakos, Inc. Method for removal of psoralens from biological fluids
CN1230212C (zh) * 1997-07-10 2005-12-07 特拉科斯有限公司 肠和膀胱炎症紊乱的治疗
AU748074B2 (en) * 1997-07-21 2002-05-30 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US6068844A (en) * 1997-12-19 2000-05-30 The United States Of America As Represented By The Department Of Health And Human Services Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof
FR2777188A1 (fr) * 1998-04-08 1999-10-15 Sephra Utilisation d'une porphyrine pour la realisation d'un medicament abaissant le nombre d'eosinophiles
US6749785B2 (en) * 1998-09-01 2004-06-15 E. I. Du Pont De Nemours And Company Multilayer structures of poly(1,3-propylene 2,6 napthalate) and poly (ethylene terephthalate)
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US7109031B2 (en) 1999-04-20 2006-09-19 Yale University Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
EP1176986B1 (en) 1999-04-20 2018-07-04 Yale University Differentiation of monocytes into functional dendritic cells
US6219584B1 (en) 1999-07-09 2001-04-17 Therakos, Inc. Method and system for determining an effective amount of light energy to delivery to fluids having targets for the light energy
US8722422B2 (en) 1999-09-03 2014-05-13 Therakos, Inc. Uninterrupted flow pump apparatus and method
US6495366B1 (en) * 1999-09-03 2002-12-17 Therakos, Inc. Uninterrupted flow pump apparatus and method
US6303154B1 (en) * 1999-09-24 2001-10-16 Boris Breivogel Chemical alteration of mammal urine and mammal blood
US6793643B1 (en) 2000-04-21 2004-09-21 Therakos, Inc. Low extracorporeal volume treatment system
US20050129617A1 (en) * 2001-06-22 2005-06-16 Rusung Tan Type1 diabetes diagnostics and therapeutics
US20070129307A1 (en) * 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
US20040076646A1 (en) * 2001-07-18 2004-04-22 Caplan Michael J. Haptenizing cancer cell components
FR2857672B1 (fr) † 2003-07-15 2005-09-16 Dacral Utilisation de l'yttrium, du zirconium, du lanthane, de cerium, du praseodyme ou du neodyme comme element renforcateur des proprietes anticorrosion d'une composition de revetement anticorrosion.
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321919A (en) 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4398906A (en) 1979-12-11 1983-08-16 Frederic A. Bourke, Jr. Method for externally treating the blood
US4428744A (en) 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4464166A (en) 1981-06-12 1984-08-07 Frederic A. Bourke, Jr. Method for externally treating the blood
US4612007A (en) 1981-06-16 1986-09-16 Edelson Richard Leslie Method and system for externally treating the blood
US4684521A (en) * 1982-12-08 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4613322A (en) 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
US4683889A (en) 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5167657A (en) 1988-11-14 1992-12-01 Baxter International Inc. Plastic composition with anti-hemolytic effect
US4999375A (en) * 1989-04-11 1991-03-12 Hoffmann-La Roche Inc. Psoralen reagent compositions for extracorporeal treatment of blood
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US20030072751A1 (en) 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
WO1993003766A1 (en) 1991-08-13 1993-03-04 Repligen Corporation Multiple antigen peptides for use as hiv vaccines
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5731160A (en) 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
AU4678993A (en) 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US5820872A (en) 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
US5462733A (en) 1993-02-04 1995-10-31 Yale University Immune system modulation using psoralens activated with visible light
ATE466869T1 (de) 1993-03-05 2010-05-15 Epimmune Inc Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
EP0692973A1 (en) 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
IL109540A0 (en) 1994-05-03 1994-08-26 Yeda Res & Dev Synthetic peptides and their use in tumor diagnosis and therapy
US5683768A (en) 1994-12-21 1997-11-04 Baxter International Inc. Plastic formulations for platelet storage containers and the like
CA2249412A1 (en) 1996-03-22 1997-09-25 Yale University Methods for inducing immune responsiveness in a subject

Also Published As

Publication number Publication date
US5651993A (en) 1997-07-29
DK0668772T3 (da) 2000-10-16
PT668772E (pt) 2000-12-29
EP0668772A4 (en) 1996-07-31
ATE195875T1 (de) 2000-09-15
EP0668772A1 (en) 1995-08-30
WO1994011016A1 (en) 1994-05-26
DE69329344D1 (de) 2000-10-05
JPH08503470A (ja) 1996-04-16
US6355238B1 (en) 2002-03-12
GR3034908T3 (en) 2001-02-28
DE69329344T2 (de) 2001-01-04
EP0668772B1 (en) 2000-08-30

Similar Documents

Publication Publication Date Title
ES2149254T3 (es) Modulacion especifica del sistema inmunitario.
ES2052645T3 (es) Acidos poliinsaturados con accion vasocinetica y formulaciones farmaceuticas y cosmeticas que los contienen.
CA957352A (en) Lighting device with beam splitter and focusing
MX9203176A (es) 1,2,4-triazolonas substituidas con fenoxietilo y composiciones farmaceuticas que las contienen.
NO141788C (no) Varmekrympbar, sammensatt muffe, saerlig for anvendelse i hoeyspentteknikken
MX9300550A (es) Estructura de fibra absorbente.
ES2054699T3 (es) Pigmentos que contienen grupos de piperidilo.
ES2063767T3 (es) Esteres aromaticos policiclicos de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen.
BE760841A (fr) Dispositif d'actionnement de frein
IT7927503A0 (it) Derivati del progesterone adattivita' anti-acne e anti-seborrea.
DE3878004D1 (de) Ringdichtungsvorrichtung.
FR3702M (fr) Médicament a base d'anguidine et de ses dérivés.
FI874450A0 (fi) Farmaceutiska sammansaettningar vid terapin av hjaernsjukdomar pao funktionell och organisk bas.
IT970385B (it) Coloranti diretti diazotabili su fibra
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
IT1109197B (it) Procedimento e dispositivo per la fusione di pece ecc..
BE800122Q (fr) Panneau d'affichage,
AR001352A1 (es) Bencenofulfonifureas y bencenosulfoniltioureas sustituidas, procedimiento para sus preparaciones, sus usos para producir preprarados farmaceuticos y los medicamentos que los contienen.
DE3886851D1 (de) Stroboskoplicht-Generator für insbesondere medizinische Zwecke.
ES2063765T3 (es) Esteres cicloalifaticos insaturados de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen.
AR192421A1 (es) Derivados de delta2-pirazolina utilizables como agentes de blanqueo optico,su procedimiento de preparacion y las composiciones que los contienen
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
IT7829848A0 (it) Procedimento di rappresentazione dinamica e dispositivo per la messa in opera del procedimento.
FI903757A0 (fi) Anordning foer att loesbart faesta en foersta del i en poeoening pao en andra del.
FR2604172B1 (fr) La 2-methyldecanaloxime et ses utilisations en tant que matiere odorante

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 668772

Country of ref document: ES